Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people taking Wegovy notice they are peeing more than usual, particularly in the early weeks of treatment. This is not listed as a direct side effect in the Wegovy prescribing information, but there are clear, well-understood reasons why it happens — and for most people it settles without any intervention. Wegovy (semaglutide) is a prescription-only medicine; a prescriber assesses your full medical picture before it is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide itself does not directly stimulate the kidneys to produce more urine. The NHS patient information for semaglutide lists the core side-effect profile as predominantly gastrointestinal (nausea, constipation, diarrhoea, indigestion) and increased urinary frequency does not appear among them. So what is going on?
The most common explanation is glycogen depletion. In the early weeks of treatment, appetite drops significantly and calorie intake falls. As the body draws on stored carbohydrate (glycogen) for energy, water that was bound to those glycogen molecules is released. Each gram of glycogen holds roughly three grams of water, so even a modest reduction in stores can produce a noticeable increase in urine output for a week or two. This is temporary.
A related factor is dietary sodium. When people eat less, they often consume less salt. Lower sodium intake encourages the kidneys to excrete more water, again producing a short-lived increase in urination. Both mechanisms tend to resolve once the body settles into its new intake pattern, usually within the first month. If you are wondering more broadly about whether Wegovy makes you pee more, we cover the full picture on that dedicated page. You can read more about the broader experience of peeing a lot on Wegovy and what the data shows.
Some people on Wegovy find they feel thirstier, particularly if nausea has suppressed their appetite for solid food and they are compensating with fluids. Drinking more will, straightforwardly, produce more urine. There is nothing wrong with this, staying well hydrated on Wegovy is genuinely important. Dehydration can amplify nausea and, in people prone to it, place unnecessary strain on the kidneys.
The practical guidance our prescribers give consistently is: aim for at least 1.5–2 litres of fluid a day, spread through the day rather than gulped in one go. For many people, keeping a water bottle nearby from the moment they wake up (before the kettle goes on for that first coffee) makes this easier to maintain. Plain water, diluted squash and herbal teas all count.
If you are also noticing unusual fatigue alongside increased thirst and urination, it is worth flagging to a clinician. This combination can occasionally point to blood sugar changes that are worth assessing, especially in people with prediabetes. Our page on energy levels on Wegovy covers the fatigue picture in more detail.
Increased urinary frequency alone, in the first weeks of treatment with no other symptoms, is generally benign. The situations that do warrant prompt attention are different in character. Pain or a burning sensation when urinating suggests a urinary tract infection, which is unrelated to Wegovy but should be treated. Blood in urine, severe pelvic pain or a sudden dramatic increase in urine output are not expected effects and need clinical review.
Separately, if you are experiencing severe vomiting or diarrhoea alongside reduced urine output rather than increased (or if your urine becomes very dark) this points to dehydration, which carries its own risks. The NHS semaglutide guidance specifically notes the risk of kidney problems arising from dehydration secondary to gastrointestinal side effects; this is one reason staying hydrated is part of standard clinical advice on Wegovy, not optional. If in doubt, our team is available seven days a week, reach the aftercare team here.
For a fuller picture of abdominal symptoms that can accompany Wegovy, including when stomach pain needs urgent assessment, our guide to abdominal pain on Wegovy is worth reading alongside this page. The January 2026 MHRA Drug Safety Update on GLP-1 medicines also flagged pancreatitis (severe, persistent stomach pain radiating to the back) as a symptom requiring urgent medical attention; the MHRA's Yellow Card service is the place to report any unexpected reactions.
The fluid loss that drives early urination is a normal part of early weight change and does not impair Wegovy's mechanism. Semaglutide works by activating GLP-1 receptors in the brain and gut, reducing appetite and slowing gastric emptying. Those processes are not affected by how much water the kidneys are moving.
It is worth saying plainly: the early weight you see on the scales in weeks one to four partly reflects this fluid shift, not fat loss. Fat loss comes later, as the sustained calorie reduction compounds over time. Some people find this disheartening if they see the scale plateau after the initial drop; it is a normal pattern, not a signal that the medicine has stopped working. Our guide to getting the most from Wegovy covers the nutrition and lifestyle factors that support continued progress. For a broader overview of how semaglutide works, our semaglutide information page has the full picture.
Wegovy requires a prescription following a clinical assessment; a prescriber reviews your health history, current medicines and BMI before any treatment is approved. If you have questions specific to your situation, the right place to start is a proper consultation rather than a general article. You can start your free consultation with our prescribers here.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.